Financhill
Buy
72

ABT Quote, Financials, Valuation and Earnings

Last price:
$133.17
Seasonality move :
3.37%
Day range:
$131.35 - $133.28
52-week range:
$99.71 - $133.28
Dividend yield:
1.68%
P/E ratio:
17.41x
P/S ratio:
5.55x
P/B ratio:
5.80x
Volume:
5M
Avg. volume:
6.8M
1-year change:
14.17%
Market cap:
$231B
Revenue:
$42B
EPS (TTM):
$7.65

Analysts' Opinion

  • Consensus Rating
    Abbott Laboratories has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of $133.08, Abbott Laboratories has an estimated downside of -0.07% from its current price of $133.17.
  • Price Target Upside
    According to analysts, the highest upside price target is $158.00 representing 18.65% upside increase from its current price of $133.17.

Fair Value

  • According to the consensus of 18 analysts, Abbott Laboratories has -0.07% downside to fair value with a price target of $133.08 per share.

ABT vs. S&P 500

  • Over the past 5 trading days, Abbott Laboratories has overperformed the S&P 500 by 2.01% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Abbott Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Abbott Laboratories has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Abbott Laboratories reported revenues of $11B.

Earnings Growth

  • Abbott Laboratories has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Abbott Laboratories reported earnings per share of $5.27.
Enterprise value:
238.4B
EV / Invested capital:
--
Price / LTM sales:
5.55x
EV / EBIT:
31.87x
EV / Revenue:
5.68x
PEG ratio (5yr expected):
0.13x
EV / Free cash flow:
36.76x
Price / Operating cash flow:
31.75x
Enterprise value / EBITDA:
23.02x
Gross Profit (TTM):
$23.2B
Return On Assets:
18.29%
Net Income Margin (TTM):
31.95%
Return On Equity:
14.78%
Return On Invested Capital:
24.77%
Operating Margin:
17.41%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $43.7B $40.1B $42B $10.2B $11B
Gross Profit $24.5B $22.1B $23.2B $5.7B $6B
Operating Income $8.4B $6.5B $6.8B $1.8B $1.9B
EBITDA $12.1B $10.5B $10.4B $2.8B $2.5B
Diluted EPS $3.91 $3.26 $7.65 $0.91 $5.27
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $20.4B $24.2B $25.2B $22.7B --
Total Assets $72.5B $75.2B $74.4B $73.2B --
Current Liabilities $11.9B $13.1B $15.5B $13.8B --
Total Liabilities $39.5B $39.2B $37.5B $34.4B --
Total Equity $33B $36B $36.9B $38.8B --
Total Debt $18.7B $18.1B $16.8B $14.7B --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $10.3B $6.5B $8.7B $1.9B $2.7B
Cash From Investing -$1.8B -$2.9B -$2.3B -$634M -$594M
Cash From Financing -$8.1B -$6.5B -$5.6B -$2.3B -$1.6B
Free Cash Flow $8.5B $4.5B $6.5B $1.3B $2.1B
ABT
Sector
Market Cap
$231B
$44.2M
Price % of 52-Week High
99.92%
48.19%
Dividend Yield
1.68%
0%
Shareholder Yield
4.16%
-0.68%
1-Year Price Total Return
14.17%
-35.43%
Beta (5-Year)
0.746
0.747
Dividend yield:
1.68%
Annualized payout:
$2.20
Payout ratio:
21.47%
Growth streak:
11 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $131.39
200-day SMA
Buy
Level $112.71
Bollinger Bands (100)
Buy
Level 111.91 - 124.03
Chaikin Money Flow
Buy
Level 2B
20-day SMA
Buy
Level $129.38
Relative Strength Index (RSI14)
Buy
Level 68.18
ADX Line
Buy
Level 42.95
Williams %R
Sell
Level -1.5117
50-day SMA
Buy
Level $120.09
MACD (12, 26)
Buy
Level 3.54
25-day Aroon Oscillator
Buy
Level 96
On Balance Volume
Neutral
Level 1.3B

Financial Scores

Buy
Altman Z-Score (Annual)
Level (5.0701)
Buy
CA Score (Annual)
Level (0.2392)
Buy
Beneish M-Score (Annual)
Level (-2.4717)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.9842)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Stock Forecast FAQ

In the current month, ABT has received 13 Buy ratings 5 Hold ratings, and 0 Sell ratings. The ABT average analyst price target in the past 3 months is $133.08.

  • Where Will Abbott Laboratories Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Abbott Laboratories share price will drop to $133.08 per share over the next 12 months.

  • What Do Analysts Say About Abbott Laboratories?

    Analysts are divided on their view about Abbott Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Abbott Laboratories is a Sell and believe this share price will rise from its current level to $109.00.

  • What Is Abbott Laboratories's Price Target?

    The price target for Abbott Laboratories over the next 1-year time period is forecast to be $133.08 according to 18 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.

  • Is ABT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Abbott Laboratories is a Buy. 13 of 18 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ABT?

    You can purchase shares of Abbott Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Abbott Laboratories shares.

  • What Is The Abbott Laboratories Share Price Today?

    Abbott Laboratories was last trading at $133.17 per share. This represents the most recent stock quote for Abbott Laboratories. Yesterday, Abbott Laboratories closed at $133.17 per share.

  • How To Buy Abbott Laboratories Stock Online?

    In order to purchase Abbott Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is SoFi Worth?
What Is SoFi Worth?

Since SoFi’s CEO began snapping up shares of the student…

Is CVX a Buy, Sell or Hold?
Is CVX a Buy, Sell or Hold?

Energy giant Chevron Corporation (NYSE:CVX) has long been a pure-play…

What Will NVIDIA Stock Be Worth in 2030?
What Will NVIDIA Stock Be Worth in 2030?

NVIDIA (NASDAQ:NVDA) has been by far one of the best…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
17
CE alert for Feb 21

Celanese [CE] is down 4.21% over the past day.

Sell
22
GLBE alert for Feb 20

Global E Online [GLBE] is down 8.41% over the past day.

Buy
72
HIMS alert for Feb 20

Hims & Hers Health [HIMS] is down 3.39% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock